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Abstract 
Nanoparticles (NPs) have great potential as advanced delivery systems for cancer immunotherapy. PEGylated-Poly-
lactide-co-glycolic acid-based (PLGA-PEG) NPs were prepared by double-emulsion solvent evaporation technique, 
using ovalbumin (OVA) as a model antigen. Glycol Chitosan and block co-polymer Pluronic F127 were used in 
order to best attain the most efficient parameters for cancer immunotherapy. OVA-loaded PLGA-PEG NPs 
presented a narrow size distribution with an average size of 167 nm witha polidisperity index (PdI)0.167 and zeta 
potential values close to neutrality (-1.66 mV), which is desired for a particulate cancer vaccine to overcome their 
premature capture by macrophages. The encapsulation efficiency (EE) and loading capacity (LC) of these NPs were 
57.5% and 29 ȝg/mg, respectively. PLGA-PEG NPs modified with Pluronic F127 presented slightly higher Z-
Average (180 nm with a PdI 0.18), and ZP (ZP -1.78 mV), but lower EE and LC (32% and 16 ȝg/mg). The effect of 
NPs on dendritic cell viabilitywas evaluated using Alamar Blue® assays.  
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1. Introduction 
Breast cancer is one of the most commonly diagnosed malignancies, being thus the leading cancer-related cause 
of death among women worldwide1. The conventional forms of treatment do not specifically target this tumor cells, 
leading to adverse effects that heavily decrease patient’s quality of life. Therefore, there is an urgent and critical 
need for new therapeutic strategies against this disease. Therapeutic cancer vaccines are used to overcome host 
immunosupression, mostly induced by tumor cells. Nanomedicine-based systems have been emerging as promising 
toolsto promote tumor associated antigens (TAAs) recognition, capture and presentation by professional antigen 
presentation cells (APCs), leading to an extensive, specific and long-lasting immune response, while the parenteral 
administration of soluble antigens would be rapidly removed from circulation2. A polymeric platform consisting on 
antigen-loaded PLGA-PEG-based nanoparticles (NPs) is being developed to ultimately deliver breast cancer 
antigens to dendritic cells (DCs) and improve their recognition by T cells within tumor microenvironment. This type 
of NPs is appealing due to their biocompatibility, biodegradability and low toxicity3. 
 
2. Results 
2.1. Preparation of nanoparticles 
Polymeric NPs were aseptically prepared by double emulsion (w/o/w) solvent evaporation method, described 
elsewhere4. Briefly, PLGA-PEG polymer was dissolved in dichloromethane (DCM) and emulsified by sonication 
(SonifierVibracell VC 375, Sonics & Materials Inc, USA) under continuous conditions for 15s at 70Wwith a glycol 
chitosan (CSg)solution that contained OVA (5% wOVA/wpolymer). A surfactant solution (internal aqueous phase; IP) 
was added to this o/w single emulsion and a second sonication was performed under the same conditions. The 
double emulsion w/o/w was added dropwise to a surfactant solution (external aqueous phase; EP), and magnetically 
stirred at 37°C during 1 h for organic solvent evaporation, thus enabling the formation ofNPs. The polymeric NPs 
were harvested three times by centrifugation (22000 x g, 45 min, 4ÛC; Beckman Coulter, lnc, Avanti® J-E 
Centrifuge JA-20, USA), and washed with ultrapure water to remove excess of surfactant and non-encapsulated 
antigen. NPs were dispersed in phosphate buffered saline (PBS pH 7.4) and kept at 4ÛC until analysis. Three groups 
of formulations were defined, depending on the nature of the surfactant used to stabilize both primary and second 
emulsions: i) sodium cholate as a surfactant in both IP and EP; ii) PVA in both IP and EP and iii) PVA in IP and 
Pluronic F127 (PF127) in EP. 
Table 1.Composition of NP formulations. 
Formulations IP Surfactant IP Surfactant EP 
NP_1b CSg ,PBS 1 % (w/v) Na-cholate 0.3 % (w/v) Na-cholate 
NP_2b 2 % (w/v) Na-cholate 
NP_3b CSg, PBS 1 % (w/v) PVA 0.3 % (w/v) PVA 
NP_4b CSg, PBS 2 % (w/v) PVA 0.3 % (w/v) PVA 
NP_4OVA CSg, OVA 
NP_5b CSg, PBS 4 % (w/v) PVA 0.3 % (w/v) PVA NP_5OVA CSg, OVA 
NP_6b CSg, PBS 10 % (w/v) PVA 0.3 % (w/v) PVA NP_6OVA CSg, OVA 
NP_7b CSg, PBS 2 % (w/v) PVA 0.3 % (w/v) PF127 
NP_8b CSg, PBS 4 % (w/v) PVA 0.3 % (w/v) PF127 NP_8OVA CSg, OVA 
NP_9b CSg, PBS 10 % (w/v) PVA 0.3 % (w/v) PF127 NP_9OVA CSg, OVA 
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OVA-loaded NPs were prepared with a loading of 5% wOVA/wpolymer. Allformulations described in 
Table 1 were prepared using PLGA-PEG polymer and 1% (w/wpolymer) CSg in aqueous IP.  
 
2.2. Physicochemical characterization ofnanoparticles 
NP mean size (Z-Average) and polidispersity index (PdI) were determined by Dynamic Light Scattering (DLS) 
using the Malvern Nano S (Malvern Instruments, UK). NP surface charge in PBS (pH 7.4) was inferred fromthe 
determination of zeta potential (ZP) that was assessed by Laser Doppler Velocimetry (LDV) with Malvern Nano Z 
(Malvern Instruments, UK). All measurements were performed in triplicate (Table 2).  
Table 2. NP physicochemical properties. (Mean ± SD; N  3)  
Formulations Z-Average (nm) PdI ZP (mV) 
NP_1b NA Flocculated system NA NP_2b 
NP_3bڢ 330 ± 2 0.239 ± 0.03 0.081 ± 0.87 
NP_4b 263 ± 15 0.266 ± 0.021 -1.21 ± 0.87 
NP_4OVA 247 ± 9 0.250 ± 0.012 -1.77 ± 0.80 
NP_5b* 150 ± 9 0.166 ± 0.030 -1.27 ± 1.05 
NP_5OVA* 167 ± 13 0.171 ± 0.022 -1.66 ± 0.79 
NP_6b* 194 ± 17 0.162 ± 0.028 -0.90 ± 0.62 
NP_6OVA* 227 ± 18 0.254 ± 0.032 -1.05 ± 0.82 
NP_7b 360 ± 30 0.363 ± 0.043 -0.95 ± 0.49 
NP_8b* 159 ± 9 0.189 ± 0.036 -1.17 ± 0.54 
NP_8OVA* 180 ± 6 0.180 ± 0.019 -1.78 ± 0.93 
NP_9b 219 ± 18 0.183 ± 0.003 -0.060 ± 0.21 
NP_9OVA NA Flocculated system NA 
*N = 9; ڢN= 2 
 
Overall, NP formulations were required to comply with two conditions: i)NPsshould present a Z-
Averagebetween 50 and 200 nm with a PdI below 0.2 and ii) NP surface charged should be close to neutrality, 
owing to lower toxicity and prevention of their premature phagocytosis by macrophages in circulation. 
Formulations were divided into three groups based on the nature of the surfactant used to promote the 
stabilization of the double emulsion (w/o/w). The first group of formulations was developed using sodium cholate as 
a surfactant of both IP and EP. However, the system was not stable, due to the increased viscosity of the IP. Sodium 
cholate was not strong enough to lower the surface tension between organic and aqueous phases, and the 
coalescence of the droplets of this emulsion occurred immediately after its preparation. As a result, sodium cholate 
was replaced by the nonionic surfactant PVA, which is a strong colloidal stabilizer. In this second group, different 
concentrations (1, 2, 4 and 10% w/v) of surfactant on IP were used in order to assess its effect onNPs 
physicochemical properties. Accordingly, higher concentrations of PVA have generally potentiated emulsion 
stability and thus the size of both plain and antigen-loaded NPs decreased when higher concentrations of surfactant 
were used to emulsify aqueous and organic phases (Table 2). Moreover, the results also show that higher surfactant 
concentrations decreased NP polidispersity. On the other hand, OVA-loaded NPs prepared with 4% (w/v) PVA 
solution had a Z-Averagesignificantly higher than NPswithoutencapsulated antigen (P = 0.074). Based on these 
results, the 4% (w/v) PVA solution used in NP formulation also promoted the formation of a nanoparticulate 
population with lowerpolidispersity values. However, when higher amount of PVA (10% (w/v)) was used as IP,the 
NP Z-Averagewas higher by 50 nm than that presented by NP prepared with 4% (w/v) PVA solution (Table 2). This 
increase in Z-Average occurred due to the higher viscosity of the 10% (w/v) PVA solution used as IP, leading to 
system instability having in consideration the small volume of this phase. All of these NPs had ZPs close to 
neutrality, between -1.8 and 0.08 mV. However, ZP of antigen-loaded NPs was slightly lower, due to the fact that 
OVA is a negatively charged protein at pH 7.4, and if absorbed on the surface of particles can influence NP surface 
charge. 
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In the third group of NP formulations, PF127 was used as a surfactant in the EP (0.3% w/v) and different 
concentrations of PVA were testedas IP (2, 4, 10% w/v). These NPs showed a similar trend as the second group. 
With increasing concentrations of surfactant in the IP (Table 2), plain NPs showed lower mean diameters. 
Formulations obtained using 4% (w/v) of PVA solution (NP_8b and NP_8OVA) presented the best parameters 
among all formulated particles within this group. Those plain NPs had an average size of 159 nm with PdI of 0.19, 
and ZP of -1.17 mV; while NPs containing OVA presented a mean diameter of 180 nm, PdI of 0.18, and ZP of -1.78 
mV. Moreover, ZP of antigen-loaded NPs is slightly more negative, owing to the charge of the protein. Interestingly, 
when 10% (w/v) PVA solution was used (NP_9OVA), the system flocculated. This is likely due to the interactions 
between OVA, PF127 and increased concentration of PVA. However, this instability was not observed for plain 
particles (NP_9b), even ifthey showed higher mean diameter in comparison to the formulation prepared with 4% 
(w/v) PVA solution.  
Overall, formulated nanosystems are expected to be suitable for parenteral administration and for the adjuvant 
effect needed to enhance host immune response, being possible to predict their extensively uptake by APCs, namely 
DCs4. 
 
2.3. Antigen loading 
The amount of encapsulated protein OVA was quantified indirectly by the MicroBCATM assay5. Supernatants 
from each centrifugation were collected in triplicates. Plain NPs were used as controls. The absorbances were 
determinedusinga Fluostar Omega microplate reader (BMG LAbtech, Germany). The Encapsulation efficiency (EE, 
%) and the Loading capacity (LC, ȝg/mg) of protein were calculated as follows (Equations 1 and 2): 
 
ࡱࡱΨ ൌ ܉ܕܗܝܖܜܗ܎܍ܖ܋܉ܘܛܝܔ܉ܜ܍܌ܘܚܗܜ܍ܑܖ
ܑܖܑܜܑ܉ܔ܉ܕܗܝܖܜܗ܎ܘܚܗܜ܍ܑܖ
ൈ ૚૙૙        (1) 
 
ࡸ࡯ ஜࢍ
࢓ࢍ
ൌ ܉ܕܗܝܖܜܗ܎܍ܖ܋܉ܘܛܝܔ܉ܜ܍܌ܘܚܗܜ܍ܑܖ
ܜܗܜ܉ܔ܉ܕܗܝܖܜܗ܎ܘܗܔܡܕ܍ܚܛ
              (2) 
Table 3. EE (%) and LC(ȝg/mg) of protein in formulated NPs. (Mean ± SD; N  12) 
Formulation EE% (w/w) LC (ȝg/mg) 
NP_4OVA* 44.5 ± 1.6 22.24 ± 0.82 
NP_5OVA 57.5 ± 13.2 28.77 ± 6.61 
NP_6OVA 59.4 ± 6.2 29.69 ± 3.10 
NP_8OVA 31.8 ± 4.0 15.87 ± 1.10 
*N = 3 
 
CSg polymer is able to protect biomolecules not only during particle formulation process, but also throughout 
release in physiologic media. The higher viscosity that is expected for IP after its dissolution maydecrease the 
interaction between proteins and the interface of droplets of the primary (w/o) emulsion, promoting the maintenance 
of their structure and activity, as well as, enhancing NPs LC by preventing protein leakage to the external aqueous 
phase. PLGA-PEG NPs prepared using CSg dissolved in 2% (w/v) PVA solution (NP_4OVA) presented an EE of 
44.5% and a LC of 22 ȝg/mg. Higher concentration of emulsifier (PVA) in the IP increased NP EE and thus led to 
higher LC (57.5% and 29 ȝg/mg for those formulated with 4% (w/v) PVA solution (NP_5OVA) and 59% and 30 
ȝg/mg for 10% (w/v) PVA solution (NP_6OVA) as IP. It is important to emphasize however that the EE and LC 
obtained for those formulations were not statistically different, suggesting that the concentration of the emulsifier 
(PVA) and its increase from 4% (w/v) to 10 % (w/v) in the IP phase does not significantly contribute to higher 
entrapment efficiencies (P > 0.05). However, NPs prepared with lower amounts of PVA in the IP (2% (w/v) PVA) 
showed significativelylower EE and LC. 
In addition, when PVA was replaced by PF127 in EP (NP_8OVA), only 32% (w/w) of protein was found to be 
associated to polymer matrix (Table 3). This shows that the co-polymeric surfactant PF127 allowed an extensive 
leakage of OVA to this external phase probably due to its lower ability to decrease free energy at this specific 
emulsion droplets interface. 
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2.4. Evaluation of protein integrity by SDS PAGE  
The assessment of protein integrity was determined by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) using Mw markers (Sigma MarkerTM, 6.5-200 kDa) and OVA standard solution 
(250ȝg/ml) as controls5. Protein band patterns of migration obtained for OVA standard solution and those extracted 
from loaded NPs (NP_OVA) are identical, suggesting that protein molecular weight had not be affected by NP 
formulation process. Additionally, these observations are corroborated by the absence of those bands at 45 kDafor 
control NPs (NP_blank). 
 
2.5. In vitro cell viability assay 
The cytotoxicity of PLGA-PEG NPs was inferred by the determination of cell viability using AlamarBlue® assay 
that was performed on immature murine DCs (JAW SII).This cell line was incubated with increasing concentrations 
of three different PLGA-PEG-based NPs: (i) NPs with CSg and PVA in IP and EP, (ii) NPs with CSg and PVA in IP 
and PF127 in EP, and (iii) NPs without CSg and with PVA in IP and PF127 in EF. DCs viability was not affected by 
any type of NPs.  
These results support the safety and biocompatibility of PLGA-PEG and CSg polymers used in the formulation 
of these polymeric NPs6-9. It reinforces the fact that the organic solvent used in the formulation process might have 
been completely evaporated during the evaporation time, as verified previously in our lab10, and thus no toxic 
residues remain in NPs. Also the excess of surfactants used in NP formulation might have been completely washed 
at the final stage of production process where three centrifugations and washings were performed. The presence of 
PEG on the surface of NPs might also contribute to the absence of a cytotoxic effect as this polymer is highly 
biocompatible due to its high hydrophilicity and due to particle surface charge close neutrality11. 
 
3. Conclusions 
From NP physicochemical properties, LC and effect on cell viability we can conclude that the most promising 
formulations are NP_5 and NP_8. NPs within this size range are expected to stay longer time in circulation and be 
efficiently taken up by DCs enhancing cross-presentation in mice. Moreover their average sizes and surface charge 
may prevent their premature capture by macrophages and also increases their ability to promote a tumor specific 
immune response. Having in consideration the results herein described, it is possible to state that the developed 
PLGA-PEG-based NPs constitute a promising platform for the delivery of tumor associated antigens to DCs, key 
players in tumor immunology.  
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